A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
for Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Drug: Obrixtamig
Sites in Baltimore +2 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT04429087·Phase 1·Recruiting·Listed Jun 2020